In type 2 diabetes, tirzepatide reduced HbA<sub>1c</sub> vs. semaglutide.
Where this comes from
- Record sourced from PubMed, PMID 34724396.
- Also identified by DOI 10.7326/ACPJ202111160-127.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Frias JP, Davies MJ, Rosenstock J, et al. <b>Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes.</b> N Engl J Med. 2021;385:503-15. 34170647.
Medical subject headings
- Diabetes Mellitus, Type 2